Suppression of MDR1 gene expression and reversal of cisplatin resistance in renal carcinoma cells by RNA interference

Tumor

Volumn 30, Issue 2, 2010, Pages 115-118

  Hao, Yi Xin ^a,b   He, Zheng Wen ^a   Du, Nan ^b   Lu, Qiong ^a   Xiao, Wen Hua ^b   Shen, Qian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

A498 cells; Cisplatin; Genes, MDR; Kidney neoplasms; RNA , small interfering

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CISPLATIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MULTIDRUG RESISTANCE PROTEIN 1; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CARCINOMA CELL; CELL CLONE; CELL PROLIFERATION; DRUG EFFECT; DRUG SENSITIVITY; GENE; GENE EXPRESSION; GENE REPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; KIDNEY CARCINOMA; LENTIVIRINAE; MDR1 GENE; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RECOMBINANT PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA SEQUENCE; WESTERN BLOTTING;

EID: 77953388364     PISSN: 10007431     EISSN: None     Source Type: Journal    
DOI: 10.3781/j.issn.1000-7431.2010.02.006     Document Type: Article

References (18)

1. VOGELZANG N J, STADLER W M. Kidney cancer [J]. Lancet, 1998,352(9141): 1691-1696.
2. MOTZER R J, RUSSO P. Systemic therapy for renal cell carcinoma [J]. J Urol,2000,163 (2) :408-417.
3. LEONARD G D, FOJO T, BATES S E. The role of ABC transporters in clinical practice [J]. Oncologist, 2003,8 (5) :411-424.
4. TIHEBAUT F. TSURUO T, HAMADA H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues [J ]. Proc Natl Acad Sci U S A, 1987,84 (21) : 7735-7738.
5. NAITO S, SAKAMOTO N, KOTOH S, et al. Expression of P- glycoprotein and multidrug resistance in renal cell carcinoma [J]. Eur Urol, 1993,24(1) : 156-160.
6. NISHIYAMA K, SHIRAHAMA T, YOSHIMURA A, et al. Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas [J]. Cancer, 1993, 71 (11) : 3611-3619.
7. ALVAREZ M, PAULL K, MONKS A, et al. Generation of a drug resistance profile by quantification of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen [J]. J Clin Invest, 1995,95 (5) :2205-2214.
8. OKANO M, KAWAMOTO S, NEZASA S, et al. Enhancement of cytotoxic effect of anticancer agents of renal cell carcinoma [J]. Nippon Hinyokika Gakkai Zasshi, 1996,87 (8) : 1041-1047.
9. GAO X K, LI Q, WANG H, et al. Antisense oligonucleotide targeting survivin induces apoptosis of renal clear-cell carcinoma cells and enhances their sensitivity to epirubicin in vitro [J]. Zhonghua Zhong Liu Za Zhi, 2005,27 (8) :468-470.
10. Chinese source
11. CIOCA D P, AOKI Y, KIYOSAWA K. RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines [J]. Cancer Gene Ther, 2003,10 (2) : 125-133.
12. YAGUE E. HIGGINS C F, RAGUZ S. Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1 [J]. Gene Ther, 2004, 11 (14) : 1170-1174.
13. NIETH C, PRIEBSCH A, STEGE A, et al. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi) [J]. FEBS Lett, 2003,545 (2-3) :144-150.
14. LOU J Y, PENG Z L, ZHENG Y, et al. Research on human ovarian cancer cell MDR1 gene silenced by siRNA [J]. Sichuan Da Xue Xue Boo Yi Xue Ban, 2007,38 (5) : 753-755.
15. ZHAO P, ZHANG Y, SUN M, et al. Reversion of multidrug resistance in human glioma by RNA interference [J]. Neurol Res, 2008,30 (6) :562-566.
16. Chinese source
17. LILLEBY W, FOSSA S D. Chemotherapy in metastatic renal cell cancer [J]. World J Urol, 2005,23 (3) :175-179.
18. NAITO S, KOGA H, YOKOMIZO A, et al. Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas [J]. World J Surg, 2000,24 (10) :1183-1186.